Bora CDMO

Bora Pharmaceuticals is an acquisitive, publicly traded CDMO that has rapidly scaled into a global contender with a broad technology portfolio spanning small molecules to biologics. Founded in Taiwan in 2007 and expanding significantly into North America, the company leverages its ten strategically located manufacturing sites to offer end-to-end services from development through commercial supply. Key milestones include major facility acquisitions from GSK and Emergent BioSolutions, the establishment of a biologics division, and securing large-scale manufacturing contracts, positioning Bora as a diversified partner for pharmaceutical companies seeking reliable, high-quality manufacturing capacity.

Integrated CDMO platform for small molecules (oral solid dose, liquids, semi-solids, nasal sprays, ophthalmics, sterile injectables) and biologics, offering formulation development, cGMP manufacturing, packaging, and analytical testing.

Operates in the highly competitive global CDMO market against large, established players like Lonza, Catalent, and Thermo Fisher Scientific, as well as numerous regional specialists. Differentiates through a broad service portfolio across small and large molecules, a strategic geographic footprint, and an aggressive acquisition-led growth strategy.